Business
Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023
Conference Call to be Held at 9:00am ET MENLO PARK, Calif.--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will
About this update from Summit Therapeutics Inc.
[{"type":"text","content":"\nConference Call to be Held at 9:00am ET\n\n\n MENLO PARK, Calif.--(BUSINESS WIRE)--\nSummit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its second quarter 2023 financial results and provide an operational update for the Company on Wednesday, August 9, 2023, before the market opens.\n\n\nSummit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through Summit’s website www.smmttx.com. An archived edition of the session will be available on our website.\n\n\nSummit Therapeutics’ Mission Statement\n\n\nTo build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate.\n\n\nWe accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position. Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.\n\n\nAbout Summit Therapeutics\n\n\nSummit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK and Cambridge, UK.\n\n\nFor more information, please visit https://www.smmttx.com and follow us on Twitter @summitplc.\n\n\nAbout Ivonescimab\n\n\nIvonescimab, known as SMT112 in the United States, Canada, Europe, and Japan (Summit’s license territories), and as AK112 in China and Australia, is a novel, ...